To Help Protect You From Another Kidney Stone Attack
Urocit-K's wax-matrix delivery system provides a slow, sustained release of medication which allows for convenient dosing, less gastrointestinal upset, and enhanced patient compliance.
Kidney stones affect more than a million Americans each year. Twelve to 24 million Americans will develop stones in their lifetime and the incidence rate has increased dramatically over the last 20 years with approximately 1,000,000 new stone cases reported each year.
If you've ever suffered from a kidney stone attack you will probably do anything in your power to prevent a recurrence. Luckily there's a specific preventative medical treatment that can greatly reduce the likelihood of your having another stone attack: Urocit-K. Urocit-K is clinically proven to inhibit the formation of most stones in over 90% of patients.
Urocit-K is a formulation of potassium citrate, for treatment of nephrolithiasis in patients with renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate of any etiology, and uric acid lithiasis, with and without uric acid stones. Urocit-K corrects the pH of the urine and elevates a naturally occurring urinary inhibitor. In addition, Urocit-K lowers saturation of calcium oxalate. This helps control the formation of new stones.
Urocit-K is available in slow-release wax-matrix tablets in 540 mg and 1080 mg strengths. Urocit-K is indicated for the treatment of calcium and uric acid kidney stones.
- Related Information
- Package Insert»
- Urocit-K Website»
- ABCs of Stone Disease Website»
Now approved for the treatment of bacterial vaginosis, the most common vaginal infection among women of childbearing age in the United States.
